Trials / Unknown
UnknownNCT04247945
Co-transplantation of MSC in the Setting of Allo-HSCT
Co-transplantation of Mesenchymal Stromal Cells in Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) .The study is aimed to identify and evaluate the potential benefits of MSCs infusion during allogeneic HSCT, with regard to the engraftment, graft versus host disease (GVHD), post-transplant relapse and survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cotransplant with MSCs | Co-transplantation of MSCs during allogeneic HSCT |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2023-12-01
- Completion
- 2025-12-01
- First posted
- 2020-01-30
- Last updated
- 2020-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04247945. Inclusion in this directory is not an endorsement.